Psychedelic 5-methoxy-N,N-dimethyltryptamine: Metabolism, pharmacokinetics, drug interactions, and pharmacological actions

Hong Wu Shen, Xi Ling Jiang, Jerrold C. Winter, Aiming Yu

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) belongs to a group of naturally-occurring psychoactive indolealkylamine drugs. It acts as a nonselective serotonin (5-HT) agonist and causes many physiological and behavioral changes. 5-MeO-DMT is O-demethylated by polymorphic cytochrome P450 2D6 (CYP2D6) to an active metabolite, bufotenine, while it is mainly inactivated through the deamination pathway mediated by monoamine oxidase A (MAO-A). 5-MeO-DMT is often used with MAO-A inhibitors such as harmaline. Concurrent use of harmaline reduces 5-MeO-DMT deamination metabolism and leads to a prolonged and increased exposure to the parent drug 5-MeO-DMT, as well as the active metabolite bufotenine. Harmaline, 5-MeO-DMT and bufotenine act agonistically on serotonergic systems and may result in hyperserotonergic effects or serotonin toxicity. Interestingly, CYP2D6 also has important contribution to harmaline metabolism, and CYP2D6 genetic polymorphism may cause considerable variability in the metabolism, pharmacokinetics and dynamics of harmaline and its interaction with 5-MeO-DMT. Therefore, this review summarizes recent findings on biotransformation, pharmacokinetics, and pharmacological actions of 5-MeO-DMT. In addition, the pharmacokinetic and pharmacodynamic drug-drug interactions between harmaline and 5-MeO-DMT, potential involvement of CYP2D6 pharmacogenetics, and risks of 5-MeO-DMT intoxication are discussed.

Original languageEnglish (US)
Pages (from-to)659-666
Number of pages8
JournalCurrent Drug Metabolism
Volume11
Issue number8
DOIs
StatePublished - Oct 2010
Externally publishedYes

Fingerprint

Methoxydimethyltryptamines
Drug interactions
Hallucinogens
Pharmacokinetics
Harmaline
Drug Interactions
Metabolism
Pharmacology
Cytochrome P-450 CYP2D6
Bufotenin
Deamination
Monoamine Oxidase
Metabolites
Serotonin
Pharmacodynamics
Serotonin Receptor Agonists
Monoamine Oxidase Inhibitors
Pharmacogenetics
Psychotropic Drugs
Genetic Polymorphisms

Keywords

  • 5-MeO-DMT
  • CYP2D6
  • Drug interaction
  • Harmaline
  • Metabolism
  • Pharmacogenetics
  • Pharmacokinetics
  • Serotonin toxicity

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry

Cite this

Psychedelic 5-methoxy-N,N-dimethyltryptamine : Metabolism, pharmacokinetics, drug interactions, and pharmacological actions. / Shen, Hong Wu; Jiang, Xi Ling; Winter, Jerrold C.; Yu, Aiming.

In: Current Drug Metabolism, Vol. 11, No. 8, 10.2010, p. 659-666.

Research output: Contribution to journalArticle

@article{e69da8de39634bc9a18fb340c986b77c,
title = "Psychedelic 5-methoxy-N,N-dimethyltryptamine: Metabolism, pharmacokinetics, drug interactions, and pharmacological actions",
abstract = "5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) belongs to a group of naturally-occurring psychoactive indolealkylamine drugs. It acts as a nonselective serotonin (5-HT) agonist and causes many physiological and behavioral changes. 5-MeO-DMT is O-demethylated by polymorphic cytochrome P450 2D6 (CYP2D6) to an active metabolite, bufotenine, while it is mainly inactivated through the deamination pathway mediated by monoamine oxidase A (MAO-A). 5-MeO-DMT is often used with MAO-A inhibitors such as harmaline. Concurrent use of harmaline reduces 5-MeO-DMT deamination metabolism and leads to a prolonged and increased exposure to the parent drug 5-MeO-DMT, as well as the active metabolite bufotenine. Harmaline, 5-MeO-DMT and bufotenine act agonistically on serotonergic systems and may result in hyperserotonergic effects or serotonin toxicity. Interestingly, CYP2D6 also has important contribution to harmaline metabolism, and CYP2D6 genetic polymorphism may cause considerable variability in the metabolism, pharmacokinetics and dynamics of harmaline and its interaction with 5-MeO-DMT. Therefore, this review summarizes recent findings on biotransformation, pharmacokinetics, and pharmacological actions of 5-MeO-DMT. In addition, the pharmacokinetic and pharmacodynamic drug-drug interactions between harmaline and 5-MeO-DMT, potential involvement of CYP2D6 pharmacogenetics, and risks of 5-MeO-DMT intoxication are discussed.",
keywords = "5-MeO-DMT, CYP2D6, Drug interaction, Harmaline, Metabolism, Pharmacogenetics, Pharmacokinetics, Serotonin toxicity",
author = "Shen, {Hong Wu} and Jiang, {Xi Ling} and Winter, {Jerrold C.} and Aiming Yu",
year = "2010",
month = "10",
doi = "10.2174/138920010794233495",
language = "English (US)",
volume = "11",
pages = "659--666",
journal = "Current Drug Metabolism",
issn = "1389-2002",
publisher = "Bentham Science Publishers B.V.",
number = "8",

}

TY - JOUR

T1 - Psychedelic 5-methoxy-N,N-dimethyltryptamine

T2 - Metabolism, pharmacokinetics, drug interactions, and pharmacological actions

AU - Shen, Hong Wu

AU - Jiang, Xi Ling

AU - Winter, Jerrold C.

AU - Yu, Aiming

PY - 2010/10

Y1 - 2010/10

N2 - 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) belongs to a group of naturally-occurring psychoactive indolealkylamine drugs. It acts as a nonselective serotonin (5-HT) agonist and causes many physiological and behavioral changes. 5-MeO-DMT is O-demethylated by polymorphic cytochrome P450 2D6 (CYP2D6) to an active metabolite, bufotenine, while it is mainly inactivated through the deamination pathway mediated by monoamine oxidase A (MAO-A). 5-MeO-DMT is often used with MAO-A inhibitors such as harmaline. Concurrent use of harmaline reduces 5-MeO-DMT deamination metabolism and leads to a prolonged and increased exposure to the parent drug 5-MeO-DMT, as well as the active metabolite bufotenine. Harmaline, 5-MeO-DMT and bufotenine act agonistically on serotonergic systems and may result in hyperserotonergic effects or serotonin toxicity. Interestingly, CYP2D6 also has important contribution to harmaline metabolism, and CYP2D6 genetic polymorphism may cause considerable variability in the metabolism, pharmacokinetics and dynamics of harmaline and its interaction with 5-MeO-DMT. Therefore, this review summarizes recent findings on biotransformation, pharmacokinetics, and pharmacological actions of 5-MeO-DMT. In addition, the pharmacokinetic and pharmacodynamic drug-drug interactions between harmaline and 5-MeO-DMT, potential involvement of CYP2D6 pharmacogenetics, and risks of 5-MeO-DMT intoxication are discussed.

AB - 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) belongs to a group of naturally-occurring psychoactive indolealkylamine drugs. It acts as a nonselective serotonin (5-HT) agonist and causes many physiological and behavioral changes. 5-MeO-DMT is O-demethylated by polymorphic cytochrome P450 2D6 (CYP2D6) to an active metabolite, bufotenine, while it is mainly inactivated through the deamination pathway mediated by monoamine oxidase A (MAO-A). 5-MeO-DMT is often used with MAO-A inhibitors such as harmaline. Concurrent use of harmaline reduces 5-MeO-DMT deamination metabolism and leads to a prolonged and increased exposure to the parent drug 5-MeO-DMT, as well as the active metabolite bufotenine. Harmaline, 5-MeO-DMT and bufotenine act agonistically on serotonergic systems and may result in hyperserotonergic effects or serotonin toxicity. Interestingly, CYP2D6 also has important contribution to harmaline metabolism, and CYP2D6 genetic polymorphism may cause considerable variability in the metabolism, pharmacokinetics and dynamics of harmaline and its interaction with 5-MeO-DMT. Therefore, this review summarizes recent findings on biotransformation, pharmacokinetics, and pharmacological actions of 5-MeO-DMT. In addition, the pharmacokinetic and pharmacodynamic drug-drug interactions between harmaline and 5-MeO-DMT, potential involvement of CYP2D6 pharmacogenetics, and risks of 5-MeO-DMT intoxication are discussed.

KW - 5-MeO-DMT

KW - CYP2D6

KW - Drug interaction

KW - Harmaline

KW - Metabolism

KW - Pharmacogenetics

KW - Pharmacokinetics

KW - Serotonin toxicity

UR - http://www.scopus.com/inward/record.url?scp=79952354609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952354609&partnerID=8YFLogxK

U2 - 10.2174/138920010794233495

DO - 10.2174/138920010794233495

M3 - Article

C2 - 20942780

AN - SCOPUS:79952354609

VL - 11

SP - 659

EP - 666

JO - Current Drug Metabolism

JF - Current Drug Metabolism

SN - 1389-2002

IS - 8

ER -